ReviewNature nanotechnology2025
Progress in cancer vaccines enabled by nanotechnology.
Review in Nature nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- CD-73 blocking black phosphorus nanosheets hitchhiked on erythrocytesMaterials today. Bio · 2026Article
- Tumor acid-triggered sericin prodrug colloidal system for enhanced photodynamic and ferroptosis therapy of breast cancer.Materials today. Bio · 2026Article
- A Glucose Metabolism-Modulatory Nanobiohybrid Vaccine Platform Promotes Anti-Tumor Immunity by Orchestrating Autophagy-Dependent Cross-Presentation and HAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- TLR9-activating cholesterol azetidine derivative-assisted therapeutic vaccines for cancer immunotherapy.Science advances · 2026Article
- Harnessing Vaccines in the Treatment of Solid Tumors: Advances, Challenges, and Future Directions.Vaccines · 2026Review
- A Bioinspired Approach to Next-Generation Vaccines in Solid Tumors with Engineered Cell Membranes.Research (Washington, D.C.) · 2026Review
- Amphiphilic Aminated [60] Fullerene Potentiates Radiofrequency Ablation for Synergistic Cancer Treatment.International journal of nanomedicine · 2026Article
- PLGA-Based Co-Delivery Nanoformulations: Overview, Strategies, and Recent Advances.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic vaccines for cancer have been pursued for decades but historically have a low rate of clinical efficacy. However, recent advances in vaccine technologies alongside new vaccination regimens and clinical trial designs are showing promise in early-stage trials, demonstrating substantial benefits in recurrence-free and overall survival in cancer patients. Nanotechnologies are playing an important role in these advances through the introduction of lipid nanoparticles and lipoplexes that can effectively deliver mRNA vaccines, improved adjuvants, and the development of technologies that efficiently target peptide vaccines to secondary lymphoid tissues. Here we review these advances in the context of parallel progress in cancer antigen discovery, nucleic acid vaccine engineering and clinical trial designs that may enable therapeutic vaccines to effectively enhance patient survival. We also discuss outstanding challenges still to be solved to maximize the efficacy of cancer vaccines.
Indexed as
Identifiers
41107547What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.